BRCA1 and ovarian cancer: Although pharmacological ablation is widely believed to be at least as effective as surgical ablation, surgery is primarily used in a risk-reduction setting for women with an increased risk of both breast and ovarian cancer due to BRCA1 or BRCA2 mutations [112,113,114].